Isconova initiates collaboration with Narvac
Isconova initiates collaboration with NPO Narvac (”Narvac”) – one of Russia’s leading companies within veterinary medicine. Initially, the aim is to develop a rabies vaccine for dog and cat for the Russian market. Isconova will own all clinical data and in addition own the commercial rights for the vaccines throughout the rest of the world, except for China, where Isconova and Narvac will co-operate through a joint venture.The agreement includes the use of Isconova’s adjuvants for developing more efficient veterinary vaccines. The first product is a Matrix M™ based rabies vaccine for dog